{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-127657","form_type":"8-K","ticker":"RNTX","cik":"0001420565","company_name":"Rein Therapeutics, Inc.","filed_at":"2024-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.341016+00:00","generated_at":"2026-06-03T02:37:46.104687+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aileron Therapeutics prices ~$20M registered direct offering of stock and warrants","bullets":["4,273,505 shares and accompanying warrants sold at combined $4.68/unit; gross proceeds ~$20M, net ~$17.9M.","Warrants exercisable at $4.68/share for 3 years; callable by Aileron after top-line LTI-03 Phase 1b results if VWAP exceeds exercise price.","Net proceeds to fund LTI-03 Phase 1b trial, working capital; cash runway projected through Q2 2025.","Offering closing on May 3, 2024; Titan Partners Group acted as sole book-runner."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-127657","json":"https://secwatch.observer/filing/0001193125-24-127657.json","markdown":"https://secwatch.observer/filing/0001193125-24-127657.md","text":"https://secwatch.observer/filing/0001193125-24-127657.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524127657/0001193125-24-127657-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524127657/d811393d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T02:37:46.104687+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"023ed1d2483c38509012478c2a03d3ed32b8f991","claim":"Rein Therapeutics, Inc. entered into Underwriting Agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC valued at combined offering price of $4.68 (effective 2024-05-01).","evidence_excerpt":"On May 1, 2024, Aileron Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Titan Partners Group LLC, a division of American Capital Partners, LLC, as underwriter (the “Underwriter”), relating to an underwritten offering (the “Offering”) of 4,273,505 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) and accompanying warrants (“Warrants”) to purchase 4,273,505 shares of Common Stock.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524127657/0001193125-24-127657-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Titan Partners Group LLC, a division of American Capital Partners, LLC"},{"label":"Value","value":"combined offering price of $4.68"},{"label":"Effective","value":"2024-05-01"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}